Tags

Type your tag names separated by a space and hit enter

Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma.
Respir Med. 1993 Feb; 87(2):133-8.RM

Abstract

To evaluate the involvement of sulphidopeptide leukotrienes on bronchial hyperresponsiveness in asthma, we examined the effects of a specific orally active leukotriene antagonist (ONO-1078) on bronchial responsiveness to methacholine in stable asthmatic subjects by a double-blinded, randomized, two-phase crossover study. Eleven asthmatic subjects received ONO-1078 (225 mg twice a day) or placebo. After 1 week administration of ONO-1078 or placebo, the subjects underwent methacholine challenge test. Test drug administrations were then discontinued for 1 week, and the subjects were then crossed over to the alternative treatment regimen. After 1 week of the alternate regimen, the subjects underwent a second methacholine challenge. Mean baseline values of forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1) and geometric mean value of provocative concentration of methacholine causing a 20% fall in FEV1 (PC20-FEV1) were equal between the first and the second methacholine test. The geometric mean value of PC20-FEV1 after the administration of ONO-1078 was 0.48 (geometric SEM, 1.48) mg ml-1, which was significantly (P < 0.01) greater than the value after the placebo administration (0.30 geometric SEM, 1.41 mg ml-1), but the baseline values of FVC and FEV1 were not altered by ONO-1078. We conclude that sulphidopeptide leukotrienes are significantly involved in the development of bronchial hyperresponsiveness in asthma but the degree of the involvement may be small.

Authors+Show Affiliations

Third Department of Internal Medicine, Kanazawa University, School of Medicine, Japan.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

8497683

Citation

Fujimura, M, et al. "Effect of a Leukotriene Antagonist, ONO-1078, On Bronchial Hyperresponsiveness in Patients With Asthma." Respiratory Medicine, vol. 87, no. 2, 1993, pp. 133-8.
Fujimura M, Sakamoto S, Kamio Y, et al. Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma. Respir Med. 1993;87(2):133-8.
Fujimura, M., Sakamoto, S., Kamio, Y., & Matsuda, T. (1993). Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma. Respiratory Medicine, 87(2), 133-8.
Fujimura M, et al. Effect of a Leukotriene Antagonist, ONO-1078, On Bronchial Hyperresponsiveness in Patients With Asthma. Respir Med. 1993;87(2):133-8. PubMed PMID: 8497683.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma. AU - Fujimura,M, AU - Sakamoto,S, AU - Kamio,Y, AU - Matsuda,T, PY - 1993/2/1/pubmed PY - 1993/2/1/medline PY - 1993/2/1/entrez SP - 133 EP - 8 JF - Respiratory medicine JO - Respir Med VL - 87 IS - 2 N2 - To evaluate the involvement of sulphidopeptide leukotrienes on bronchial hyperresponsiveness in asthma, we examined the effects of a specific orally active leukotriene antagonist (ONO-1078) on bronchial responsiveness to methacholine in stable asthmatic subjects by a double-blinded, randomized, two-phase crossover study. Eleven asthmatic subjects received ONO-1078 (225 mg twice a day) or placebo. After 1 week administration of ONO-1078 or placebo, the subjects underwent methacholine challenge test. Test drug administrations were then discontinued for 1 week, and the subjects were then crossed over to the alternative treatment regimen. After 1 week of the alternate regimen, the subjects underwent a second methacholine challenge. Mean baseline values of forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1) and geometric mean value of provocative concentration of methacholine causing a 20% fall in FEV1 (PC20-FEV1) were equal between the first and the second methacholine test. The geometric mean value of PC20-FEV1 after the administration of ONO-1078 was 0.48 (geometric SEM, 1.48) mg ml-1, which was significantly (P < 0.01) greater than the value after the placebo administration (0.30 geometric SEM, 1.41 mg ml-1), but the baseline values of FVC and FEV1 were not altered by ONO-1078. We conclude that sulphidopeptide leukotrienes are significantly involved in the development of bronchial hyperresponsiveness in asthma but the degree of the involvement may be small. SN - 0954-6111 UR - https://www.unboundmedicine.com/medline/citation/8497683/Effect_of_a_leukotriene_antagonist_ONO_1078_on_bronchial_hyperresponsiveness_in_patients_with_asthma_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0954-6111(93)90141-L DB - PRIME DP - Unbound Medicine ER -